MURRAY HILL, N.J.--(BUSINESS WIRE)--June 25, 2008--C. R. Bard, Inc. (NYSE: BCR) announced today that Sharon M. Alterio, 45, has been promoted to the position of Group Vice President with responsibility for Bard's international businesses, effective December 1, 2008. Sharon replaces Amy S. Paul, who will retire from Bard at the end of the year after 26 years of service.

Sharon joined Bard in October 2004 as President of Bard Medical Division (BMD). Under her leadership, BMD acquired Venetec International, Inc. in 2006, which brought the StatLock(R) catheter stabilization product line into the division's portfolio. Sharon's team also completed Bard's largest clinical trial, which resulted in FDA clearance in late 2007 to market the Agento(TM) IC silver-coated endotracheal tube for the prevention of ventilator assisted pneumonia.

Prior to joining Bard, Sharon worked at Baxter Healthcare in a number of positions of increasing responsibility, most recently as Vice President, Global Therapeutic Marketing for the Renal Division. Sharon earned a Bachelor of Science degree in Computer Science and a Masters of Management degree from Northwestern University.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

CONTACT: C. R. Bard, Inc.
Investor Relations:
Eric J. Shick, 908-277-8413
Vice President, Investor Relations
or
Media Relations:
Holly P. Glass, 703-754-2848
Vice President, Government and Public Relations

SOURCE: C. R. Bard, Inc.